British DNA producer Touchlight announced that it has completed the redevelopment and expansion of its UK manufacturing facility.
The expanded state-of-the-art facility’s manufacturing capacity has tripled and is now capable of producing more than 8kg a year. This exceeds the current, but growing, global supply of plasmid DNA for genetic medicine. The new facility has 11 suites and includes two class B filling suites with class A filling cabinets, warehousing, together with a quality control laboratory capability and has already received a successful customer quality audit from a Big Pharma company.
The company noted that its proprietary doggybone DNA (dbDNA) overcomes the technical challenges associated with efficiently mass-producing plasmid DNA. The patented dbDNA technology produces a minimal, linear, double stranded, covalently closed DNA vector through an enzymatic manufacturing process. dbDNA is uniquely positioned for the rapid, synthetic, and scalable manufacture of GMP DNA using a small, simple footprint. The technology can incorporate genes from 500bp to 20kb and accommodate sequences typically unstable as plasmid DNA in E. coli, such as those found in viral vector and mRNA production.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze